Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1779-1786

  Klussmann, Jens P ^a   Mooren, Jeroen J ^b   Lehnen, Martin ^a   Claessen, Sandra M H ^b   Stenner, Markus ^a   Huebbers, Christian U ^a   Weissenborn, J Soenke ^b   Wedemeyer, Inga ^a   Preuss, Simon F ^a   Straetmans, Jos M J A A ^b   Manni, Johannes J ^b   Hopman, Anton H N ^b   Speel, Ernst Jan M ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TUMOR CLASSIFICATION; WART VIRUS;

ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 3; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEASIBILITY STUDIES; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTORS; SMOKING; SURVIVAL RATE;

EID: 63449130280     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1463     Document Type: Article

References (62)

1. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ. Chang ing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000;11:489-95.
2. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005;103:1843-9.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71 -96.
4. CarvalhoAL, Nishimoto IN, Califano JA, Kowalski LP.Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. IntJ Cancer 2005;114:806 -16.
5. Preuss SF, DinhV, Klussmann JP, Semrau R, Mueller RP, Guntinas-Lichius O. Outcome of multimodal treatment fororopharyngeal carcinoma: a singleinstitution experience. Oral Oncol 2007;43:402-7.
6. Syrjanen S. Human papillomaviruses in head and neck carcinomas. N Engl J Med 2007;356:1993 -5.
7. KreimerAR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467 -75.
8. Klussmann JP,Weissenborn S,Wieland U, et al. Prevalence, distribution and viral load ofhuman papilloma-virus 16 DNA in tonsillar carcinomas. Cancer 2001;92:2875 -84.
9. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
10. Ragin CC,Taioli E. Survival of squamous cell carci noma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int JCancer2007;121:1813-20.
11. Reimers N, Kasper HU,Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int JCancer2007;120:1731-8.
12. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and non-smokers with HPV16-associated tonsillar carcinomas. Int J Cancer 2008;122:2656-64.
13. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100: 261-9.
14. Lo ML, DAngelo M, Procaccini M, et al. Expression of cell cycle markers and human papillomavirus infection in oral squamous cell carcinoma: use of fuzzy neural networks. Int J Cancer 2005;115:717-23.
15. Preuss SF, Weinell A, Molitor M, et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer 2008;98:627-32.
16. HafKamp HC, Mooren J, Claessen SMH, et al. P21cip1/Waf1 expression is strongly associated with HPV-positivetonsillar carcinoma and a favorable prognosis. Modern Pathol 2009.
17. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and over expression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003; 107:394-400.
18. BalzV, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003;63: 1188-91.
19. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001; 93:232-5.
20. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003;162:747-53.
21. Wittekindt C, Gultekin E, Weissenborn SJ, Dienes HP, Pfister HJ, Klussmann JP. Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol 2005;62:72-80.
22. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavrus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465-72.
23. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744-54.
24. Klussmann JP, Weissenborn SJ, Wieland U, et al. Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? Med Microbiol Immunol 2003;192:129-32.
25. Mao L, HongWK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311 -6.
26. Veltman JA, van Weert I, Aubele M, et al. Specific steps in aneuploidization correlatewith loss ofhetero-zygosity of 9p21, 17p13 and 18q21 in the progression of pre-malignant laryngeal lesions. Int J Cancer 2001;91:193-9.
27. Bockmuhl U, Schluns K, Schmidt S, Matthias S, Petersen I. Chromosomal alterations during metastasis ormation of head and neck squamous cell carcinoma. Genes Chromosomes Cancer 2002;33:29-35.
28. Gollin SM. Chromosomal alterations in squamouscell carcinomas of the head and neck: window to the biology of disease. Head Neck 2001;23:238-53.
29. Beder LB, Gunduz M, Ouchida M, et al. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 2003;83: 99-105.
30. WreesmannVB, Shi W,Thaler HT, et al. Identification ofnovel prognosticators ofoutcome in squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22:3965-72.
31. Bockmuhl U, Schluns K, Kuchler I, Petersen S, Petersen I. Genetic imbalances with impact on survival in head and neck cancer patients. Am J Pathol 2000; 157:369-75.
32. Heselmeyer K, Schrock E, du Manoir S, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 1996;93:479-84.
33. Huang FY, KwokYK, Lau ET, Tang MH, NgTY, Ngan HY. Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. CancerGenet Cytogenet 2005;157:42-8.
34. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
35. Heselmeyer-Haddad K, Sommerfeld K,White NM, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 2005;166:1229-38.
36. Wieland U, Brockmeyer NH, Weissenborn SJ, et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006;142: 1438-44.
37. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual. 6th ed. Berlin, New York: Springer; 2002.
38. Pindbord JJ, Reichart PA, Smith CJ, van derWaal I. Histological typing ofcancerand precancerof theoral mucosa. 2nd ed. Berlin, Heidelberg, New York: Springer-Verlag; 1997.
39. Speel EJ, Scheidweiler AF, Zhao J, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrinepancreatictumors: gain of 9Q34 is an early event in insulinomas. Cancer Res 2001;61:5186-92.
40. ForastiereA, Koch W,Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
41. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implica tions for field cancerization. Cancer Res 1996;56: 2488-92.
42. Smeets SJ, Braakhuis BJ, Abbas S, et al. Genomewide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558-64.
43. Dahlgren L, Mellin H,Wangsa D, et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 2003;107:244-9.
44. Hopman AH, Theelen W, Hommelberg PP, et al. Genomic integration of oncogenic HPV and gain of the human telomerase geneTERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 2006;210:412-9.
45. Martin CL, Reshmi SC, Ried T, et al. Chromosomal imbalancesin oral squamouscell carcinoma: Examination of 31 cell lines and review of the literature. OralOncol 2008;44:369-82. Epub 2007 Aug 2.
46. Qian J, Massion PP. Role of chromosome 3q amplification in lung cancer. J Thorac Oncol 2008;3:212-5.
47. Smith L, Liu SJ, Goodrich L, et al. Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nat Genet 1998; 19:39-46.
48. LockwoodWW, Chari R, Chi B, Lam WL. Recentadvances in array comparative genomic hybridization technologies and their applications in human genetics. Eur J Hum Genet 2006;14:139-48.
49. MaYY,Wei SJ, LinYC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-44.
50. Kanao H, EnomotoT, KimuraT, et al. Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in uterine cervical cancer. Cancer Res 2005;65: 8640-5.
51. Lopez CD, Martinovsky G, Naumovski L. Inhibition of cell death by ribosomal protein L35a. Cancer Lett 2002;180:195-202.
52. Fan CS, Wong N, Leung SF, et al.Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol 2000;31:169-78.
53. Ragin CC, Taioli E, Weissfeld JL, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 2006;95:1432-8.
54. Reshmi SC, Roychoudhury S, Yu Z, et al. Inverted duplication pattern in anaphase bridges confirms the breakage-fusion-bridge (BFB) cycle model for 11q13 amplification. Cytogenet Genome Res 2007; 116:46-52.
55. JinY, Hoglund M, Jin C, et al. FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer 1998;22:312-20.
56. Wentzensen N,Vinokurova S, von Knebel DM. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;64:3878-84.
57. Choi YW, Bae SM, Kim YW, et al. Gene expression profiles in squamous cell cervical carcinoma using array-based comparativegenomichybridization analysis. Int J Gynecol Cancer 2007;17:687-96.
58. Steenbergen RD, Hermsen MA, Walboomers JM, et al. Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Cancer Res 1995;55:5465-71.
59. Fromont G,Valeri A, Cher M, et al. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer. Prostate 2005;65:341 -6.
60. Hansen LL, Yilmaz M, Overgaard J, Andersen J,kruseTA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998;58:2166-9.
61. Bosch FX, Andl C, Abel U, KartenbeckJ. E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int J Cancer 2005;114:779-90.
62. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol 2007;17:31 -41.